WIth Pfizer announcement of a massive consolidation overall by Jan 1st, the Publicis cso reps will be on the outside looking in with any job postings.
1) This will be one of the biggest downsizings in Pfizer's history and many top notch performing reps will be displaced that have Rheum and Derm and GI experience, relationships, and proven sales success with key doctors that the current Xeljanz team doesn't. (they havent performed for a blockbuster product and need to upgrade talent).
Even if a Publicis rep is good, then why doesnt Xeljanz have 10-20% market share after 9months??? It has to be the reps. They cant do anything with the Pfizer reps for now, but 50% of salesforce is cso which they can upgrade half of the sales force with these openings.
2) Pfizer doesnt want to keep any cso reps because they haven't added value to the product. ZERO impact with national 2% share in 9months on a blockbuster product???
THis is the reason Pfizer didnt do a rollover with the cso reps. They even opened postings up to internal and external candidates. It will overlap the companies massive downsizing in Oct so many internal candidates.
They dangled that "cso can interview and compete" carrot to keep focus for 6 months and not have a drop off in activity. Plus the Publicis management have a nice retention bonus if they dont have any cso turnover.
If you are waiting for an opportunity for a Pfizer position and think that you have an advantage because you sold Xeljanz for 9months and generated a 2-3% market share-- think again. If anybody is telling you different, they have hidden selfish agendas. Will be luck if 10-15% are retained (10-12 reps nationally). And those will probably be in the rural markets with low talent pool.
Pfizer is serious about upgrading talent, inside word is that Pfizer reps-- even the long time Enbrel reps and DMs, will be forced into a PLAN this fall and given 6 months to improve performance or terminated. Every Pfizer rep in this division has their job on the line (RM, DMs, and reps)--- and with the timing of massive layoffs by Jan, need to show fast improvement quickly. First year goal was originally 20% market share then reduced to 10% market share-- half way and nationally 2% is not good for anybody-- CSO or Pfizer!
1) This will be one of the biggest downsizings in Pfizer's history and many top notch performing reps will be displaced that have Rheum and Derm and GI experience, relationships, and proven sales success with key doctors that the current Xeljanz team doesn't. (they havent performed for a blockbuster product and need to upgrade talent).
Even if a Publicis rep is good, then why doesnt Xeljanz have 10-20% market share after 9months??? It has to be the reps. They cant do anything with the Pfizer reps for now, but 50% of salesforce is cso which they can upgrade half of the sales force with these openings.
2) Pfizer doesnt want to keep any cso reps because they haven't added value to the product. ZERO impact with national 2% share in 9months on a blockbuster product???
THis is the reason Pfizer didnt do a rollover with the cso reps. They even opened postings up to internal and external candidates. It will overlap the companies massive downsizing in Oct so many internal candidates.
They dangled that "cso can interview and compete" carrot to keep focus for 6 months and not have a drop off in activity. Plus the Publicis management have a nice retention bonus if they dont have any cso turnover.
If you are waiting for an opportunity for a Pfizer position and think that you have an advantage because you sold Xeljanz for 9months and generated a 2-3% market share-- think again. If anybody is telling you different, they have hidden selfish agendas. Will be luck if 10-15% are retained (10-12 reps nationally). And those will probably be in the rural markets with low talent pool.
Pfizer is serious about upgrading talent, inside word is that Pfizer reps-- even the long time Enbrel reps and DMs, will be forced into a PLAN this fall and given 6 months to improve performance or terminated. Every Pfizer rep in this division has their job on the line (RM, DMs, and reps)--- and with the timing of massive layoffs by Jan, need to show fast improvement quickly. First year goal was originally 20% market share then reduced to 10% market share-- half way and nationally 2% is not good for anybody-- CSO or Pfizer!